Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferoxamine
Drug ID BADD_D00596
Description Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indications and Usage Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Marketing Status Prescription; Discontinued
ATC Code V03AC01
DrugBank ID DB00746
KEGG ID D03670
MeSH ID D003676
PubChem ID 2973
TTD Drug ID D0FJ8A
NDC Product Code Not Available
Synonyms Deferoxamine | Desferrioxamine | Desferioximine | Deferoxamine B | Desferrioxamine B | Deferoximine | Deferrioxamine B | Desferroxamine | Desferrioxamine B Mesylate | Mesylate, Desferrioxamine B | Deferoxamine Mesilate | Mesilate, Deferoxamine | Deferoxamine Mesylate | Mesylate, Deferoxamine | Deferoxamine Methanesulfonate | Methanesulfonate, Deferoxamine | Desferal
Chemical Information
Molecular Formula C25H48N6O8
CAS Registry Number 70-51-9
SMILES CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.008747%Not Available
Gastrointestinal pain07.01.05.005--
Generalised tonic-clonic seizure17.12.01.002--Not Available
Haemoglobin decreased13.01.05.0030.008747%Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Hepatic failure09.01.03.0020.001521%
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.0040.008747%Not Available
Hepatitis C11.05.06.004; 09.01.09.0050.005831%Not Available
Hepatomegaly09.01.05.0010.005831%Not Available
Hypersensitivity10.01.03.0030.011662%
Hypotension24.06.03.0020.017494%
Hypothyroidism05.02.03.001; 14.11.01.0120.005831%
Immobile26.01.01.002--Not Available
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.0020.005324%Not Available
Influenza22.07.02.001; 11.05.03.0010.005831%Not Available
Injection site pain08.02.03.010; 12.07.03.011--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Lenticular opacities06.06.01.003--Not Available
Leukocytosis01.02.01.0020.005831%
Leukopenia01.02.02.001--Not Available
Liver disorder09.01.08.0010.008747%Not Available
Local reaction08.01.03.012--Not Available
Local swelling08.01.03.013--Not Available
Lung infiltration22.01.02.0040.001521%Not Available
Maculopathy06.09.03.0070.014578%Not Available
Malaise08.01.01.0030.017494%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages